Gamma knife radiosurgery is a radiation type of therapy used to treat tumors, vascular malformations, and other abnormalities in the brain. Gamma knife radiosurgery is different from other forms of stereotactic radiosurgery (SRS), as in gamma knife surgery there is no incision. Moreover, gamma knife radiosurgery uses specialized equipment to focus about 200 tiny beams of radiation on a tumor or other target with submillimeter accuracy. A strong dose of radiation is delivered to the place where all the beams meet, as compared to effect of each beam. The precision of brain stereotactic radiosurgery results in minimal radiation delivery to healthy tissues surrounding the target. This type of radiation treatment is usually performed, if a person is suffering from a tumor or other abnormality in the brain that is difficult to reach with standard neurosurgery, or a person is not healthy enough to undergo standard surgery, and if a person prefers a less invasive treatment.
Market Dynamics
Increasing collaboration between major players is expected to drive the global gamma knife market. For instance, in March 2020, Elekta and San Jose Moscati Hospital teamed up to equip new center in Queretaro State with comprehensive range of radiotherapy solutions, to treat cancer patients in Mexico. The agreement comprises a broad array of cancer treatment and radiotherapy support systems such as Elekta Unity, Leksell Gamma Knife, and brachytherapy using Flexitron, Versa HD linear accelerator, and MOSAIQ oncology information system.
However, growth of the global gamma knife market is expected to be hampered over the forecast period, owing to increasing FDA recalls. For instance, in May 2017, the U.S. Food and Drug Administration recalled the Leksell Gamma Knife Icon developed by Elekta, Inc., under Class 2 Device Recall due to safety issues.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook